Everolimus Heart Transplant NDA Pending
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A 12-month trial comparing concentration-controlled everolimus and reduced cyclosporine (Novartis' Neoral) to Pfizer's CellCept (mycophenolate mofetil) plus standard Neoral has been completed, according to ClinicalTrials.gov.